Conduit Pharmaceuticals Inc. Warrant (CDTTW)

• Market cap: $1.23M
• 1 day: -9.18%
• 5 days: -6.32%
• 1 month: 27.14%
• 3 months: -50.00%
• 6 months: 0.00%
• Year to date: 34.85%
• 1 year: -89.15%
• 5 years: -94.76%
• 10 years: -94.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Employees: 6

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

301% more capital invested

Capital invested by funds: $60.3K [Q4 2024] → $242K (+$182K) [Q1 2025]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 18 [Q4 2024] → 19 (+1) [Q1 2025]

0.79% less ownership

Funds ownership: 6.33% [Q4 2024] → 5.54% (-0.79%) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2